Acute toxic effects of sustained-release verapamil in chronic renal failure.

Author: BiermanM H, HammekeM D, PritzaD R

Paper Details 
Original Abstract of the Article :
Four hypertensive patients with chronic renal insufficiency or end-stage renal disease who were treated with sustained-release verapamil hydrochloride subsequently developed acute toxic effects. All four patients developed varying degrees of atrioventricular heart block, hypotension, hyperkalemia, m...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://pubmed.ncbi.nlm.nih.gov/1843183

データ提供:米国国立医学図書館(NLM)

Verapamil: A Cautionary Tale in the Desert of Renal Impairment

Verapamil, a medication used to treat hypertension, can present unique challenges in patients with renal impairment. This study examines the potential toxic effects of sustained-release verapamil in individuals with chronic renal insufficiency or end-stage renal disease. The research highlights the importance of careful monitoring and individualized treatment approaches in this patient population.

Verapamil: A Potentially Toxic Journey for Patients with Renal Impairment

The study reveals that sustained-release verapamil can accumulate in patients with renal impairment, leading to potentially serious adverse effects, such as heart block, hypotension, hyperkalemia, and hepatic dysfunction. It's like navigating a desert with a dwindling water supply—careful management and monitoring are crucial.

Navigating the Desert of Renal Impairment

This research emphasizes the importance of individualized treatment approaches for patients with renal impairment. Careful monitoring and close communication with healthcare providers are vital for ensuring safety and optimal outcomes.

Dr.Camel's Conclusion

This study underscores the potential risks associated with verapamil in patients with renal impairment. It's a reminder that navigating the desert of chronic illness requires careful consideration of medication choices and vigilant monitoring.

Date :
  1. Date Completed 1991-11-07
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

1843183

DOI: Digital Object Identifier

1843183

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.